Novavax Inc (NVAX)
$4.48
0.24 (4.99%)
NVAX Stock Quote Delayed 15 Minutes
Previous Close
$4.72
Market Cap
1.71B
PE Ratio
-7.35
EPS
-0.61
Volume (Avg. Vol.)
617,543
Day's Range
4.38 - 4.73
52-Week Range
0.34 - 7.90
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Novavax News: Why NVAX Stock Is Shooting Higher Today
Novavax news for Thursday concerning an accelerated approval pathway for one of the company's drugs has NVAX stock soaring higher.
Novavax News: Why NVAX Stock Is Plunging Today
Novavax news concerning the results from the company's recent trail of its drug ResVax has NVAX stock falling on Thursday.
Novavax Stock Is a Cautionary Tale for Speculators
Novavax stock is plunging on Thursday after failing a Phase 3 study. That sets up a breakdown instead of a breakout in NVAX stock.
Novavax (NVAX) Stock Upgraded to Buy
As one of the 657 companies in the GICS Health Technology sector Novavax Inc (NASDAQ:NVAX) is a constituent of the 337 company Biotechnology GICS industry group within this sector. NVAX has a market value of $0.6 billion which is in the top half of its industry group. Portfolio Grader's current ranking for NVAX puts it 107 among the 337 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 213 among the 657 companies in the sector, and number 1,498 in the nearly 5,000 company Portfolio Grader universe.
Earnings Visibility Hamper Novavax (NVAX) Rating
Novavax Inc (NASDAQ:NVAX) ranks in the upper half of its industry group, Biotechnology, and in the upper half of its sector group, Health Technology, with a market value of $0.4 billion. From an investment attractiveness vantage point, NVAX is ranked in the top half of the sector with a ranking of 264 among the 656 companies in the sector; the ranking for NVAX by Portfolio Grader places it 127 among the 337 companies in this industry group, giving it an above-average position and number 1,942 in the 5000 company Portfolio Grader company universe.
40 Biotechnology Stocks to Sell Now
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
40 Biotechnology Stocks to Sell Now
The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
NVAX Stock: Novavax Attempts to Claw Its Way Back From the Pits
Novavax (NVAX) stock is an absolute wild card, but it sure is scrappy. Regardless, it's bound to see a shift in analyst expectations soon.
Hottest Manufacturing Stocks Now – FATE OCRX AEGR WVE
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
3 Stocks to Watch Friday: Novavax, Inc. (NVAX), Oracle Corporation (ORCL) and Unilever plc (ADR) (UL)
Novavax (NVAX) is on its last legs, Oracle (ORCL) is dropping and Unilever (UL) is in early discussions to buy out Jessica Alba's Honest Co.
Biggest Movers in Manufacturing Stocks Now – LXRX LPTN CLCD SNSS
The following stocks were moving the Manufacturing sector today.
33 Biotechnology Stocks to Sell Now
This week, the ratings of 33 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
23 Biotechnology Stocks to Sell Now
This week, the overall grades of 23 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Novavax, Inc.: NVAX Stock Gets Gutted — Can It Still Double?
Novavax, Inc. (NASDAQ:NVAX) is leading the biotech charge downward today on dismal earnings that left investors questioning the bull case.
Biggest Movers in Manufacturing Stocks Now – BNSO BIOA COKE XONE
The following stocks were moving the Manufacturing sector today.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
